|Publication number||US7364752 B1|
|Application number||US 09/709,829|
|Publication date||Apr 29, 2008|
|Filing date||Nov 10, 2000|
|Priority date||Nov 12, 1999|
|Publication number||09709829, 709829, US 7364752 B1, US 7364752B1, US-B1-7364752, US7364752 B1, US7364752B1|
|Inventors||James J. Fort, Steven L. Krill, Devalina Law, Yihong Qiu, William R. Porter, Eric A. Schmitt|
|Original Assignee||Abbott Laboratories|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (104), Non-Patent Citations (30), Referenced by (2), Classifications (25), Legal Events (6) |
|External Links: USPTO, USPTO Assignment, Espacenet|
Solid dispersion pharamaceutical formulations
US 7364752 B1
A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
1. A pharmaceutical composition comprising ritonavir, wherein ritonavir in said composition is formulated as a solid dispersion of amorphous ritonavir in a matrix including a water soluble polymer.
2. A pharmaceutical composition of claim 1, comprising a gelatin capsule which encapsulates said solid dispersion.
3. A pharmaceutical composition of claim 1 which is a tablet comprising said solid dispersion.
4. The pharmaceutical composition of claim 1, wherein said water soluble polymer is PEG.
5. The pharmaceutical composition of claim 1, wherein said water soluble polymer is PEG 8000.
6. The pharmaceutical composition of claim 1, wherein said solid dispersion further comprises (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).
7. The pharmaceutical composition of claim 1, further comprising a pharmaceutically-acceptable filler, diluent, lubricant or disintegrant.
8. The pharmaceutical composition of claim 1, wherein said solid dispersion is ground and formulated into a delivery system.
9. A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 1 to a mammal in need of such treatment.
10. A method of treating an HIV infection comprising administering the pharmaceutical composition of claim 6 to a mammal in need of such treatment.
This application claims the benefit of U.S. Provisional Application for Patent No. 60/165,018, filed Nov. 12, 1999.
TECHNICAL FIELD OF THE INVENTION
The instant invention relates to the fields of pharmaceutical and organic chemistry, and provides novel solid dispersion pharmaceutical formulations with enhanced bioavailability.
BACKGROUND OF THE INVENTION
One measure of the potential usefulness of an oral dosage form of a pharmaceutical agent is the bioavailability observed after oral administration of the dosage form. Various factors can affect the bioavailability of a drug when administered orally. These factors include aqueous solubility, drug absorption throughout the gastrointestinal tract, dosage strength, and first pass effect. Aqueous solubility is one of the most important of these factors. When a drug has poor aqueous solubility, attempts are often made to identify salts or other derivatives of the drug which have improved aqueous solubility. When a salt or other derivative of the drug is identified which has good aqueous solubility, it is generally accepted that an aqueous solution formulation of this salt or derivative will provide the optimum oral bioavailability. The bioavailability of the aqueous oral solution formulation of a drug is then generally used as the standard or ideal bioavailability against which other oral dosage forms are measured.
For a variety of reasons, including patient compliance and taste masking, a solid dosage form, such as a capsule or tablet, is usually preferred over a liquid dosage form. However, oral solid dosage forms of a drug generally provide a lower bioavailability than oral solutions of the drug. One goal of the development of a suitable solid dosage form is to obtain a bioavailability of the drug that is as close as possible to the ideal bioavailability demonstrated by the oral aqueous solution formulation of the drug.
An alternative dosage form is a solid dispersion. The term solid dispersion refers to the dispersion of one or more active ingredients in an inert carrier or matrix at solid state prepared by the melting (or fusion), solvent, or melting-solvent methods. (Chiou and Riegelman, Journal of Pharmaceutical Sciences, 60, 1281 (1971)). The dispersion of a drug or drugs in a solid diluent by mechanical mixing is not included in this category. Solid dispersions may also be called solid-state dispersions.
Retroviral protease inhibiting compounds are useful for inhibiting HIV proteases in vitro and in vivo, and are useful for inhibiting HIV (human immunodeficiency virus) infections and for treating AIDS (acquired immunodeficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability. Examples of HIV protease inhibiting compounds include
- (2S,3S,5S)-5-(N—(N—((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);
- (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane (ABT-378);
- N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)—N′-(t-butylcarboxamido)-piperazinyl))-pentaneamide(indinavir);
- 1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;
- VX-478; DMP-323; DMP-450; AG1343 (nelfinavir); BMS 186,318; SC-55389a; BILA 1096 BS; and U-140690, or combinations thereof.
While some drugs would be expected to have good solubility in organic solvents, it would not necessarily follow that oral administration of such a solution would give good bioavailability for the drug.
Polyethylene glycol (PEG) solid dispersion formulations are generally known to improve the dissolution and bioavailability of many compounds. However, Aungst et al. has recently demonstrated that this was unable to improve the bioavailability of an HIV protease inhibitor with a cyclic urea structural backbone, called DMP 323 (Aungst et al., International Journal of Pharmaceutics, 156, 79 (1997)).
Thus, it would be a significant contribution to the art to provide a solid dispersion pharmaceutical formulation of a retroviral protease inhibitor which is more stable and has enhanced bioavailability.
SUMMARY OF THE INVENTION
The instant invention provides a stable solid dispersion comprising a retroviral protease inhibitor and PEG having improved bioavailability.
Also provided by the instant invention is a pharmaceutical composition comprising a stable solid dispersion as described above with a pharmaceutically acceptable carrier, diluent, or excipient.
Additionally provided by the instant invention is a method for preparing a stable solid dispersion as described above.
The instant invention still further provides a method of treating an HIV infection comprising administering an effective amount of a stable solid dispersion as described above to a mammal in need of such treatment.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 illustrates the dispersion of amorphous ABT-538 in PEG 8000.
FIG. 2 illustrates the bioavailability of a dispersion of amorphous ABT-538 in PEG 8000.
FIG. 3 illustrates the in vivo-in vitro correlation of ABT-538.
FIG. 4 illustrates the dissolution of ABT-378.
FIG. 5 illustrates the dissolution of nelfinavir.
DETAILED DESCRIPTION OF THE INVENTION
This invention pertains to the preparation of solid dispersion systems for protease inhibitors with improved dissolution and oral bioavailability.
A solid (molecular) dispersion comprising an HIV protease inhibiting compound may be prepared by dissolving or dispersing the HIV protease inhibiting compound in a sufficient amount of an organic solvent followed by dispersion into a suitable water soluble carrier. Suitable organic solvents include pharmaceutically acceptable solvents such as methanol, ethanol, or other organic solvents in which the protease inhibitor is soluble. Suitable water soluble carriers include polymers such as polyethylene glycol (PEG), pluronics, pentaeythritol, pentaeythritol tetraacetate, polyoxyethylene stearates, poly-ε-caprolactone, and the like.
The organic solvent (preferably ethanol) may then be evaporated away, leaving the drug dispersed/dissolved in the molten matrix, which is then cooled. The solid matrix has the compound finely dispersed (molecular dispersion) in such a way that dissolution of the drug is maximized, thus improving the bioavailability of a drug exhibiting dissolution rate limited absorption. Ease of manufacturing is also an attribute to this type of formulation. Once the organic solvent is evaporated to yield a solid mass, the mass may be ground, sized, and optionally formulated into an appropriate delivery system. Thus, by improving the dissolution of a poorly water soluble drug, the drug in a suitable carrier may be filled into a gelatin capsule as a solid, or the matrix may potentially be compressed into a tablet.
The delivery system of the present invention results in increased solubility and bioavailability, and improved dissolution rate of the HIV protease inhibiting compound.
Other pharmaceutically-acceptable excipients may be added to the formulation prior to forming the desired final product. Suitable excipients include lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, disintegrants, and the like, that might be needed to prepare a capsule or tablet.
The resulting composition comprising the HIV protease inhibiting compound may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into capsules, or made into tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The composition can be used to improve the oral bioavailability and solubility of said HIV protease inhibiting compound.
Total daily dosing of HIV protease inhibitors may be administered to a human in single or divided doses in amounts, for example, from 0.001 to 1000 mg/kg body weight daily, but more usually 0.1 to 50 mg/kg body weight daily. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drugs administered in combination and the severity of the particular disease undergoing therapy.
ABT-538 (ritonavir) was preferably used as the HIV protease inhibitor in the instant invention. Additionally, two other protease inhibitors, ABT-378 and nelfinavir mesylate, were tested in solid dispersions to demonstrate the improved dissolution which can be achieved with this system.
One aspect of the instant invention provides a solid dispersion of a compound of formula I
A compound of formula I is an HIV protease inhibitor marketed by Abbott Laboratories under the tradename Norvir®, with the common name ritonavir [(2S,3S,5S)-5-(N—(N—((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane]. This and other compounds as well as methods for preparing the same are disclosed in U.S. Pat. Nos. 5,648,497 and 5,541,206, the disclosures of which are herein incorporated by reference.
Additional HIV protease inhibitors which may be formulated into a solid dispersion include compounds of formula II
A compound of formula II is known as ABT-378 ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S— (1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane). This and other compounds, as well as methods for preparing same, are identified in U.S. Pat. No. 5,914,332, the disclosure of which is herein incorporated by reference.
A compound of formula III provided hereinbelow is known as nelfinavir mesylate (marketed under the tradename Viracept® by Agouron Pharmaceuticals, Inc. in La Jolla, Calif.), and is another HIV protease inhibitor which may be formulated into a solid dispersion.
The following Examples are provided to further illustrate the present invention.
EXAMPLES Example 1 Dispersion Preparations
A. Ritonavir (ABT-538) Dispersion Preparation:
The samples were prepared by dissolving ABT-538 in a small volume of 200 proof ethanol in a 250 ml round bottom flask. The flask was vortexed and then placed in a water bath maintained at 75° C. The PEG 8000 was added to the hot alcohol solution with continual swirling until the PEG melted. The flask was then attached to a rotary evaporator, immersed in the water bath (75° C.) under vacuum for 15 minutes to remove the ethanol. After the majority of ethanol had evaporated, the flask was immersed in an ice bath for 15 minutes. The contents of the flask were then vacuum dried at room temperature for 6 hours. The solid was transferred to a crystallization dish and placed under vacuum overnight to remove residual ethanol. The material was then ground and sifted. Particles ranging in size from to 420 μm were used for further studies. The drug used for these dispersions were 10, 20 and 300 w/w.
B. ABT-378 Dispersion Preparation:
A 10% dispersion was prepared using an alcoholic solution of ABT-378 (ca. 0.1 g/ml) by the same method as described in section A above.
C. Nelfinavir mesylate Dispersion Preparation:
Nelfinavir mesylate is available from Agouron Pharmaceuticals, Inc. under the tradename Virucept®.
A 10% dispersion was prepared using an alcoholic solution of nelfinavir (ca. 0.035 g/ml) by the same method as described in section A above.
The potency values of all the dispersions as well as the dissolution sample concentrations were determined via HPLC.
The in vitro dissolution data of the ABT-538 dispersions compared with ABT-538 in 0.1N HCl (shown in FIG. 1, n=3±SD unless otherwise indicated) show that the dispersions markedly improved the dissolution rate of the drug. Drug loading decreases the rate of drug release in a rank order. A bioavailability study was conducted in dogs with the above ABT-538 dispersions to elicit the drug load effects in vivo. Eight beagle dogs, obtained from Marshall Research Animals (North Rose, N.Y.), were utilized in this study. The animals were fasted overnight prior to dosing in each period but water was allowed ad libitum. Approximately 30 minutes prior to dosing, each dog received a 100 μg/kg subcutaneous dose of histamine. Capsules containing 5 mg/kg of 10, 20 and 30% solid dispersion (formulations A, B and C, respectively) were tested against crystalline drug as a reference in a four-way crossover study.
Each dog received the dose followed by approximately 10 ml of water. A washout period of approximately 1 week was used to separate each dosing period. The plasma samples were analyzed by a method reported by Marsh et al. (Marsh, K. C., Eiden, E. and McDonald, E. Determination of Ritonavir, a new HIV Protease Inhibitor, in Biological Samples Using Reversed-Phase High-Performance Liquid Chromatography. J. Chromatography B. 704 (1997) 307-313.)
The results of the study are shown in FIG. 2. The results show that the solid dispersions improve absorption compared to the reference. An in vitro—in vivo correlation was established. A plot of the AUC versus the amount dissolved in 20 min, shown in FIG. 3, is a straight line, indicating excellent correlation.
The dissolution properties of the two additional protease inhibitors (ABT-378 and nelfinavir mesylate) were also determined. The in vitro dissolution data (FIG. 4) of the ABT-378 dispersion compared with reference clearly shows that the preparation of a dispersion markedly improves dissolution rate of the drug. The variability in the release rate from the dispersion is due to the fact that the preparation of these dispersions had not been optimized to completely overcome the wetting problem of the drug. Despite this, the improvements observed are significant [95% confidence intervals shown].
The nelfinavir mesylate solid dispersion also exhibits an improved in vitro dissolution rate compared to the neat drug (FIG. 5).
Solid dispersions of HIV protease inhibitors (for example, ABT-538 (ritonavir), ABT-378, and nelfinavir mesylate) markedly improve the dissolution rate of these drugs. This improvement of dissolution rate is reflected in the improvement of bioavailability. An excellent in vivo—in vitro correlation established for the dispersions suggests that the in vitro dissolution reflects in vivo bioavailability for these systems.
Example 2 Stability of Dispersion in Molten PEG 8000
The stability of the dispersion of ABT-538 in PEG 8000 in the molten state at 70° C. was examined. Individual approximately 5 mg quantities of the dispersion (aged for 6 weeks at room temperature) were placed in 4 ml glass vials. These vials, with the exception of the initial time point, were placed in a
70° C. oven which was sampled at pre-determined intervals, chilled in ice water and placed in the freezer until HPLC analysis. After all samples were collected, they were analyzed for ABT-538 content by HPLC. The HPLC system consisted of a Hitachi AS 4000 autosampler, SP 8800 ternary pump, Applied Biosystems 783 detector, and PE Nelson Data acquisition system. Other chromatographic details included a Regis Little Champ 5 cm C-18 column, a mobile phase consisting of an aqueous solution of 0.1% trifluoroacetic acid in 10 mM aqueous tetramethyl ammonium perchlorate (TMAP)/acetonitrile/methanol (55/40/5). The flow rate was 1 ml/minute, the wavelength of detection was 205 nm, and the injection volume was 100 μl. Standard curves of peak area of ABT-538 vs. concentration in the range of interest were compared with experimentally obtained area counts.
Example 3 Additional Protocol for Oral Bioavailability Studies
Dogs (beagle dogs, mixed sexes, weighing 7-14 kg) are fasted overnight prior to dosing, but are permitted water ad libitum. Each dog receives a 100 μg/kg subcutaneous dose of histamine approximately 30 minutes prior to dosing. Each dog receives a single solid dosage form corresponding to a 5 mg/kg dose of the drug. The dose is followed by approximately 10 milliliters of water. Blood samples are obtained from each animal prior to dosing and at 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug administration. The plasma is separated from the red cells by centrifugation and frozen (−30° C.) until analysis. The concentrations of parent drug is determined by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The parent drug area under the curve is calculated by the trapezoidal method over the time course of the study. The absolute bioavailability of each test composition is calculated by comparing the area under the curve after oral dosing to that obtained from a single intravenous dose. Each capsule or capsule composition is evaluated in a group containing at least six dogs. The values reported are averages for each group of dogs.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4758427||Jan 20, 1987||Jul 19, 1988||Ciba-Geigy Corporation||Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone|
|US4769235||Jan 28, 1985||Sep 6, 1988||New York University||Protein of sporozite stage of plasmodium parasites; peptide vaccine for malaria|
|US4769236||May 19, 1986||Sep 6, 1988||Elan Corporation, Plc||Medicaments with a high degree of solubility and method for their production|
|US4801460||Apr 6, 1987||Jan 31, 1989||Basf Aktiengesellschaft||Preparation of solid pharmaceutical forms|
|US4851438||Oct 20, 1986||Jul 25, 1989||S. C. Johnson & Son, Inc.||Nonionic surfactants; ethoxylate of alkylphenol; primary alcohol or mercaptan|
|US4880585||Dec 22, 1988||Nov 14, 1989||Basf Aktiengesellschaft||Continuous method of tableting|
|US4904699||Dec 7, 1987||Feb 27, 1990||Bauer Kurt H||Nifedipine concentrate stabilized against the influence of light and a process for its preparation|
|US4957681||Apr 3, 1989||Sep 18, 1990||Basf Aktiengesellschaft||Continuous accurate metering, shaping|
|US4996058||Sep 12, 1988||Feb 26, 1991||Ciba-Geigy Corporation||Covered retard forms|
|US5073379||Aug 25, 1989||Dec 17, 1991||Basf Aktiengesellschaft||Continuous preparation of solid pharmaceutical forms|
|US5145683||Jan 30, 1990||Sep 8, 1992||Ethical Pharmaceuticals, Ltd.||Nifedipine-containing pharmaceutical compositions and process for the preparation thereof|
|US5405616||Apr 30, 1992||Apr 11, 1995||Alfatec Pharma Gmbh||Cryopellets; time-releasing agents; used in the field of pharmacy, cosmetics diagnostics, analysis and dietetics|
|US5456923||Dec 23, 1993||Oct 10, 1995||Nippon Shinyaku Company, Limited||Method of manufacturing solid dispersion|
|US5490990||Jun 21, 1993||Feb 13, 1996||Basf Aktiengesellschaft||Production of solid pharmaceutical depot forms|
|US5525628||Jun 9, 1993||Jun 11, 1996||Edmond Pharma S.R.L.||Salts of a glutathione alkylester and anaminoacids|
|US5541206||Apr 25, 1995||Jul 30, 1996||Abbott Laboratories||Retroviral protease inhibiting compounds|
|US5545628||Jan 10, 1995||Aug 13, 1996||Galephar P.R. Inc.||Pharmaceutical composition containing fenofibrate|
|US5552159||Sep 23, 1993||Sep 3, 1996||Basf Aktiengesellschaft||Solid depot drug form|
|US5559158||Aug 31, 1994||Sep 24, 1996||Abbott Laboratories||Pharmaceutical composition|
|US5610193 *||May 22, 1996||Mar 11, 1997||Abbott Laboratories||Pharmaceutical composition|
|US5641516||Aug 7, 1995||Jun 24, 1997||Basf Aktiengesellschaft||Shaping a water-soluble melt of a cellulose ether and a cellulose ether or an addition polymer with a drug or crop-protective material; uniformly sustained release|
|US5648497||Mar 24, 1995||Jul 15, 1997||Abbott Laboraotries||Retroviral protease inhibiting compounds|
|US5725878||May 4, 1995||Mar 10, 1998||Abbott Laboratories||Pharmaceutical composition comprising HIV protease inhibiting compounds|
|US5727878||Oct 17, 1996||Mar 17, 1998||Cdf Corporation||Liner for a mixing container and an assembly and method for mixing fluid components|
|US5741519||Mar 12, 1996||Apr 21, 1998||Basf Aktiengesellschaft||The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process|
|US5773025||Apr 18, 1996||Jun 30, 1998||Edward Mendell Co., Inc.||Sustained release heterodisperse hydrogel systems--amorphous drugs|
|US5889051||Jul 15, 1997||Mar 30, 1999||Development Center For Biotechnology||Stabilization of prostaglandin drug|
|US5897910||Dec 22, 1995||Apr 27, 1999||Basf Aktiengesellschaft||Production of covered tablets|
|US5914332 *||Nov 21, 1996||Jun 22, 1999||Abbott Laboratories||Retroviral protease inhibiting compounds|
|US5939099||Feb 1, 1996||Aug 17, 1999||Basf Aktiengesellschaft||Solid active extrusion compound preparations containing low-substituted hydroxypropylcellulose|
|US5945123||Apr 2, 1998||Aug 31, 1999||K-V Pharmaceutical Company||Determining known pharacokinetic parameters of therapeutical substance, number of doses to be administered during 24 hours and determining time at which dose will be adminstered by considering both schedule and physiological anamolies|
|US5945127||Mar 9, 1996||Aug 31, 1999||Basf Aktiengesellschaft||Storage-stable drug form|
|US5948426||Apr 30, 1998||Sep 7, 1999||Jefferies; Steven R.||Method and article to induce hematopoietic expansion|
|US5948436||Mar 13, 1995||Sep 7, 1999||Abbott Laboratories||Protease inhibitor|
|US5969181||Jun 10, 1997||Oct 19, 1999||Breitenbach; Joerg||Preparation of salts of pharmaceutical active substances which have acidic groups|
|US6001391||Mar 10, 1998||Dec 14, 1999||Basf Aktiengesellschaft||Molding a melt of a polymeric binder with or without at least one active ingredient, there being at least one solid product, which may contain an active ingredient incorporated into the still plastic composition during the molding step|
|US6009690||Dec 22, 1995||Jan 4, 2000||Basf Aktiengesellschaft||Process and apparatus for the production of divisible tablets|
|US6027747||Sep 11, 1998||Feb 22, 2000||Terracol; Didier||Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions|
|US6037157||Jun 26, 1996||Mar 14, 2000||Abbott Laboratories||Method for improving pharmacokinetics|
|US6063821||Mar 9, 1996||May 16, 2000||Basf Aktiengesellschaft||Antiinflammatory agents and extrusion for administering and antipyretics|
|US6066334||Mar 10, 1998||May 23, 2000||Basf Aktiengesellschaft||Polyvinyl acetate, n-vinylpyrrolidone-containing polymer, water swellable agent, and water insoluble dusting agent; high speed release|
|US6083518||Jun 19, 1996||Jul 4, 2000||Bioglan Ab||Bactericide cleaning compounds with surfactants|
|US6120802||Oct 23, 1996||Sep 19, 2000||Basf Aktiengesellschaft||Coextruding thermoplastic, pharmacologically acceptable polymeric binder which is soluble or swellable in physiological environment and pharmaceutical active ingredient; shaping coextruded material to required drug form|
|US6132659||Dec 22, 1995||Oct 17, 2000||Basf Aktiengesellschaft||Rolling and counter rolling, molding and melting|
|US6150424||Aug 21, 1997||Nov 21, 2000||Basf Aktiengesellschaft||Comprising a melt-processable thermoplastic polymer and a volatile, physiologically acceptable blowing agent|
|US6187342||Sep 30, 1996||Feb 13, 2001||Basf Aktiengesellschaft||Solid medicaments obtained by extrusion of an isomalt-containing polymer-active substance melt|
|US6197781||Aug 13, 1999||Mar 6, 2001||Novartis Ag||Spray drying mixture of rapamycin suspension and carrier|
|US6197787 *||Oct 1, 1999||Mar 6, 2001||Sanofi-Synthelabo||Pharmaceutical formulations containing poorly soluble drug substances|
|US6221368||Sep 11, 1997||Apr 24, 2001||Basf Aktiengesellschaft||As polymeric binder poly(meth)acrylates or their copolymers with (meth)acrylic acid or polyvinylpyrrolidone or copolymers thereof with vinyl esters|
|US6248363||Nov 23, 1999||Jun 19, 2001||Lipocine, Inc.||Solid carriers for improved delivery of active ingredients in pharmaceutical compositions|
|US6251434||Jan 17, 1997||Jun 26, 2001||Basf Aktiengesellschaft||Preparations of non-steroidal analgesics|
|US6281282||Apr 24, 1997||Aug 28, 2001||Basf Aktiengesellschaft||Adjustment ph; salt formation|
|US6290990||Apr 15, 1995||Sep 18, 2001||Basf Aktiengesellschaft||Slow-release matrix pellets and the production thereof|
|US6294192||Feb 26, 1999||Sep 25, 2001||Lipocine, Inc.||Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents|
|US6318650||May 13, 1998||Nov 20, 2001||Basf Aktiengesellschaft||Method for producing small-particle preparations of biologically active substances|
|US6322816||Jul 21, 1998||Nov 27, 2001||Basf Aktiengesellschaft||Fast-acting analgesic|
|US6350398||Aug 30, 1999||Feb 26, 2002||Basf Aktiengesellschaft||Process for producing coated solid dosage forms|
|US6383471||Apr 6, 1999||May 7, 2002||Lipocine, Inc.||Drug delivery|
|US6387401||Aug 21, 1996||May 14, 2002||Basf Aktiengesellschaft||Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process|
|US6423256||Oct 13, 1999||Jul 23, 2002||Basf Aktiengesellschaft||Process for producing solid dosage forms|
|US6436440||Apr 1, 1999||Aug 20, 2002||Basf Aktiengesellschaft||Use of N-vinyllactam-or-N-vinylamine-containing copolymers as matrix for producing solid pharmaceutical and cosmetic presentations|
|US6451339||Jul 2, 2001||Sep 17, 2002||Lipocine, Inc.||Drug delivery|
|US6462093||Aug 8, 1996||Oct 8, 2002||Nissan Chemical Industries, Ltd.||Method for converting sparingly water-soluble medical substance to amorphous state|
|US6465011||May 29, 1999||Oct 15, 2002||Abbott Laboratories||Formulations comprising lipid-regulating agents|
|US6488939||Dec 3, 1999||Dec 3, 2002||Abbott Laboratories||Cleavable solid dosage forms and method for the production thereof|
|US6547997||Nov 9, 1998||Apr 15, 2003||Abbot Laboratories||Method for producing solvent-free noncrystalline biologically active substances|
|US6599528||Mar 17, 2000||Jul 29, 2003||Abbott Gmbh & Co. Kg||Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substances|
|US6599931||Sep 18, 1999||Jul 29, 2003||Abbott Gmbh & Co. Kg||Test system for characterizing the compatibility of bioactive substances and polyvinylpyrrolidone|
|US6608198||Feb 27, 2001||Aug 19, 2003||Abbott Laboratories||Crystalline pharmaceutical|
|US6669879||Aug 27, 1999||Dec 30, 2003||Abbott Laboratories||Method for producing solid dosing forms|
|US6669883||Jan 14, 2000||Dec 30, 2003||Abbott Laboratories||Method and device for producing different solid dosage forms|
|US6692767||Sep 18, 1998||Feb 17, 2004||Shire Laboratories Inc.||Solid solution beadlet|
|US6730319||May 23, 2002||May 4, 2004||Hoffmann-La Roche Inc.||Pharmaceutical compositions having depressed melting points|
|US6733781||Dec 6, 2000||May 11, 2004||Wyeth||Fast dissolving tablet|
|US6737005||Nov 22, 1999||May 18, 2004||Abbott Gmbh & Co. Kg||Method of producing solid dosage forms|
|US6787157||Mar 10, 1998||Sep 7, 2004||Abbott Laboratories||Multiphase active ingredient-containing formulations|
|US6834310||Feb 26, 2002||Dec 21, 2004||Science Applications International Corp.||Preventing packet flooding of a computer on a computer network|
|US6894171||Jul 19, 1999||May 17, 2005||Abbott Laboratories||Protease inhibitors; viricides; purity, crystal structure|
|US7014810||Dec 15, 2000||Mar 21, 2006||Abbott Gmbh & Co. Kg||Method of producing solid shape forms containing an active ingredient|
|US7148359||May 4, 2005||Dec 12, 2006||Abbott Laboratories||Protease inhibitors; viricides; purity, crystal structure|
|US7229641||Aug 1, 2002||Jun 12, 2007||Capricorn Pharma, Inc.||For the delivery of prophylactic and therapeutic active materials to a mammal; formed by molding or compression, with an additional heating step being preferred.|
|US20010006650||Sep 18, 1998||Jul 5, 2001||Beth A. Burnside||Therapeutic agent dispersed in solid beadlet comprising at least 20% by weight of at least one hydrophobic long chain fatty acid or ester thereof and at least 3.0% by weight of at least one surfactant|
|US20020006443||Dec 20, 2000||Jan 17, 2002||Curatolo William J.||Pharmaceutical compositions providing enhanced drug concentrations|
|US20020114833||Dec 6, 2000||Aug 22, 2002||Abu-Izza Khawla A.||Fast dissolving tablet|
|US20020161884||Feb 26, 2002||Oct 31, 2002||Science Applications International Corporation||Agile network protocol for secure communications with assured system availability|
|US20020187188||Aug 1, 2002||Dec 12, 2002||Cherukuri S. Rao||Rapid-melt compositions methods of making same and methods of using same|
|US20030015814||Dec 15, 2000||Jan 23, 2003||Harald Krull||Device and method for producing solid shape containing an active ingredient|
|US20030039686||May 23, 2002||Feb 27, 2003||Karsten Maeder||Increased absorption; aqueous solution containing fatty acid, or salt thereof|
|US20030054038||Jun 17, 2002||Mar 20, 2003||Crew Marshall D.||Mixture of drug and enteric acid polymer; neutralization|
|US20030072801||Jun 20, 2002||Apr 17, 2003||Pfizer Inc.||Pharmaceutical compositions comprising drug and concentration-enhancing polymers|
|US20030091630||Oct 25, 2001||May 15, 2003||Jenny Louie-Helm||Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data|
|US20030091643||Jun 18, 2002||May 15, 2003||Friesen Dwayne T.||Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability|
|US20030096791||May 30, 2002||May 22, 2003||Cima Labs Inc.||Taste masking of highly water-soluble drugs|
|US20030104063||Jun 19, 2002||Jun 5, 2003||Babcock Walter C.||Low-solubility drug and a matrix combined with a concentration- enhancing polymer. improves stability and/ or enhances concentration|
|US20030153608||Mar 15, 2001||Aug 14, 2003||Markus Maegerlein||Torasemide-containing pharmaceutical preparations|
|US20030161884||May 29, 2001||Aug 28, 2003||Jorg Rosenberg||Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base|
|US20040001888||Jun 26, 2003||Jan 1, 2004||Biopharm Solutions Inc.||Solid dosage forms for rapid dissolution of poorly soluble drugs|
|US20040013697||May 29, 2001||Jan 22, 2004||Gunther Berndl||Self-emulsifying active substance formulation and use of this formulation|
|US20040013734||Jun 10, 2003||Jan 22, 2004||Pfizer Inc.||Pharmaceutical solid dispersions|
|US20040014817||Sep 19, 2001||Jan 22, 2004||Joerg Rosenberg||Stable dosage forms containing ubiquinones|
|US20040029892||Aug 2, 2001||Feb 12, 2004||Joerg Rosenberg||Compositions and dosage forms for application in the oral cavity in the treatment of mykoses|
|US20040062802||Aug 20, 2003||Apr 1, 2004||Hermelin Victor M.||Maximizing effectiveness of substances used to improve health and well being|
|US20070249692 *||Mar 27, 2007||Oct 25, 2007||Fort James J||Inhibitors of crystallization in a solid dispersion|
|WO1996023499A1 *||Jan 19, 1996||Aug 8, 1996||Bernard Charles Sherman||Extended-release solid oral dosage forms of drugs having low solubility in water|
|1||Aungst, B.J., et al., "Improved Oral Bioabilability of an HIV Protease Inhibitor Using Gelucire 44/14 and Labrasol Vehicles", B.T. Gattefosse, 87:49-54 (1994).|
|2||Awni, W., et al., "Significantly Reduced Food Effect and Pharmacokinetic Variability with a Novel Lopinavir/Ritonavir Tablet Formulation", third IAS Conf. On HIV Pathogenesis and Treatment, (2005).|
|3||B. J. Aungst, et al., "Amphiphilic Vehicles Improve the Oral Bioavailability of a Poorly Soluble HIV Protease Inhibitor at High Doses", International Journal of Pharmaceutics, 156 (1997) 79-88.|
|4||B. J. Aungst, et al., "Improved Oral Bioavailability of an HIV Protease Inhibitor Using Celucire 44/14 and Labrasol Vehicles", B.T. Gattetosse, 87 (1994), 49-54.|
|5||BASF Fine Chemicals, "ExAct Excipients & Actives for Pharma", BASF, 2:1-16 (1999).|
|6||Bouma, M.G., et al., "Novel Therapeutic Delivery Systems", J. of Contr. Rel., 87:199-308 (2003).|
|7||Breitenbach, J., "Melt Extrusion Can Bring New Benefits to HIV Therapy: The Example of Kaletra (R) Tablets", Amer. :J. of Drug Deliv., 4(2):61-64 (2006).|
|8||Breitenbach, J., "Melt extrusion: from process to drug delivery technology", Eur. J. of Pharm. & Biopharm., 54:107-117 (2002).|
|9||Chiou, W.L. & Riegelman, S., "Pharmaceutical Applications of Solid Dispersion Systems", J. of Pharm. Sci., 60(9):1281-1301 (1971).|
|10||Corrigan, I.I. & Healy, A.M., "Surfactants in Pharmaceutical Products and Systems", Encycl. Of Pharm. Tech., 2639-2653 (2002).|
|11||Devalina Law et al., Physicochemical Considerations in the Preparation of Amorphous Ritonavir-Poly(ethyleneglycol) 6000 Soild Dispersions, J. Pharm. Sciences, (Aug. 2001), 1015-1025, 90(8).|
|12||Ford, J.L., "The Current Status of Solid Dispersions", Pharm. Acta Helv., 61(3):69-88 (1986).|
|13||Forster, A., et al., "Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis", Intn'l J. of Pharm., 226:147-161 (2001).|
|14||Hulsmann, S., et al., "Melt extrusion-an alternative method for enhancing the eissolution rate of 17beta-estradiol hemihydrate", Eur. J. of Pharm. & Biopharm., 49:237-242 (2000).|
|15||International Search Report & Written Opinion from PCT/US2004/027401 dated May 8, 2006.|
|16||J. L. Ford, "The Current Status of Solid Dispersions", Pharm Acta Helv. 61. Nr. 3, (1986) 69-88.|
|17||Karanth, H., et al., "Industrially Feasible Alternative Approaches in the Manufacture of Solid Dispersions: A Technical Report", AAPS PharmSciTech, 7(4):Art. 87 (2006).|
|18||Law, D., et al., "Physicochemical Considerations in the Preparation of Amorphous Ritonavir-Poly(ethylene glycol) 8000 Solid Dispersions", J. of Pharm. Sci., 90(8):1015-1025 (2001).|
|19||Law, D., et al., "Ritonavir-PEG 8000 Amorphous Solid Dispersions: In Vitro and in Vivo Evaluations", J. of Pharm. Sci., 93(3):563-570 (2004).|
|20||Palmieri, G.F., et al., "Characterization and dissolution studies of PEG 4000/fenofibrate solid dispersions", S.T.P. Pharma Sci., 6(3):188-194 (1996).|
|21||Physicians Desk Reference, online . . . Norvir, Fenofibrate, and Greiseosulvin, not dated.|
|22||Physicians Desk Reference, online excert, PDR Electronic Library, not dated.|
|23||Serajuddin, A.T.M., "Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems and Recent Breakthroughs", J. of Pharm. Sci., 88(10):1058-1066 (1999).|
|24||U.S. Appl. No. 09/438,994, filed Nov. 12, 1999, Fort et al.|
|25||U.S. Appl. No. 09/438,994, James J. Fort, et al., filed Nov. 12, 1999.|
|26||U.S. Appl. No. 11/691,819, filed Mar. 27, 2007, Fort et al.|
|27||U.S. Appl. No. 11/691,819, James J. Fort, et al., filed Mar. 27, 2007.|
|28||U.S. Appl. No. 11/773,185 Joerge Rosenberg, et al., filed Jul. 3, 2007.|
|29||W. L. Chiou, et al., "Pharmaceutical Applications of Solid Dispersion System", Journal of Pharmaceutical Sciences, 60 (9), (1971), 1281-1302.|
|30||Zhu, T., et al., "New Tablet Formulation of Lopinavir/Ritonavir is Bioequivalent to the Capsule at a Dose 800/200 mg", 48<SUP>th </SUP>Int. Conf. On Antimic. Agents & Chem., (ICAAC), (2005).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8025899||Aug 25, 2004||Sep 27, 2011||Abbott Laboratories||Solid pharmaceutical dosage form|
|WO2013018050A2||Aug 1, 2012||Feb 7, 2013||Ranbaxy Laboratories Limited||Dissolution enhanced controlled drug delivery system for poorly water soluble drugs|
| || |
|U.S. Classification||424/455, 424/486, 514/772, 514/274, 514/937, 424/464, 424/484, 514/365, 514/772.3|
|International Classification||A61K9/48, A61K8/72, A61K31/425, A61K31/505, A61K9/20|
|Cooperative Classification||A61K31/425, Y10S514/937, A61K9/2072, A61K9/167, A61K9/1641, A61K31/505|
|European Classification||A61K31/425, A61K31/505, A61K9/16K, A61K9/16H6D, A61K9/20K|
|Feb 5, 2013||AS||Assignment|
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:029756/0593
Owner name: ABBVIE INC., ILLINOIS
Effective date: 20120801
|Aug 7, 2012||RR||Request for reexamination filed|
Effective date: 20120624
|Sep 23, 2011||FPAY||Fee payment|
Year of fee payment: 4
|Nov 9, 2010||RR||Request for reexamination filed|
Effective date: 20100825
|Jan 6, 2009||CC||Certificate of correction|
|Jan 21, 2008||AS||Assignment|
Owner name: ABBOTT LABORATORIES, ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FORT, JAMES J.;KRILL, STEVEN L.;LAW, DEVALINA;AND OTHERS;REEL/FRAME:020391/0522;SIGNING DATES FROM 20010320 TO 20010411